Notice: file_put_contents(): Write of 8530 bytes failed with errno=28 No space left on device in /var/www/tg-me/post.php on line 50
Readhub | Telegram Webview: readhub_cn/254219 -
Telegram Group & Telegram Channel
智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验

智飞生物子公司自主研发的双价痢疾结合疫苗即将在孟加拉国启动Ⅲ期临床试验,该疫苗用于预防福氏志贺菌和宋内氏志贺菌引起的细菌性痢疾,是国际首个可同时预防这两种志贺菌感染的疫苗,目前全球尚无同类产品获批上市。细菌性痢疾为全球性公共卫生问题,每年发病人数达1.647亿,主要由福氏和宋内氏志贺菌引起。智飞生物致力于推动更多优质疫苗上市,守护人类健康。

媒体报道
智飞生物四价流脑结合疫苗获得Ⅲ期临床试验总结报告 医药魔方
智飞生物:四价流脑结合疫苗获得Ⅲ期临床试验总结报告 界面
智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验 医药魔方

事件追踪
2024-10-09 智飞生物:四价流感病毒裂解疫苗(儿童型)申请生产注册获得受理
2024-08-21 智飞生物26价肺炎球菌结合疫苗启动Ⅰ/Ⅱ期临床试验

#热门话题



tg-me.com/readhub_cn/254219
Create:
Last Update:

智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验

智飞生物子公司自主研发的双价痢疾结合疫苗即将在孟加拉国启动Ⅲ期临床试验,该疫苗用于预防福氏志贺菌和宋内氏志贺菌引起的细菌性痢疾,是国际首个可同时预防这两种志贺菌感染的疫苗,目前全球尚无同类产品获批上市。细菌性痢疾为全球性公共卫生问题,每年发病人数达1.647亿,主要由福氏和宋内氏志贺菌引起。智飞生物致力于推动更多优质疫苗上市,守护人类健康。

媒体报道
智飞生物四价流脑结合疫苗获得Ⅲ期临床试验总结报告 医药魔方
智飞生物:四价流脑结合疫苗获得Ⅲ期临床试验总结报告 界面
智飞生物双价痢疾结合疫苗将于孟加拉国启动Ⅲ期临床试验 医药魔方

事件追踪
2024-10-09 智飞生物:四价流感病毒裂解疫苗(儿童型)申请生产注册获得受理
2024-08-21 智飞生物26价肺炎球菌结合疫苗启动Ⅰ/Ⅱ期临床试验

#热门话题

BY Readhub


Warning: Undefined variable $i in /var/www/tg-me/post.php on line 283

Share with your friend now:
tg-me.com/readhub_cn/254219

View MORE
Open in Telegram


Readhub Telegram | DID YOU KNOW?

Date: |

Look for Channels Online

You guessed it – the internet is your friend. A good place to start looking for Telegram channels is Reddit. This is one of the biggest sites on the internet, with millions of communities, including those from Telegram.Then, you can search one of the many dedicated websites for Telegram channel searching. One of them is telegram-group.com. This website has many categories and a really simple user interface. Another great site is telegram channels.me. It has even more channels than the previous one, and an even better user experience.These are just some of the many available websites. You can look them up online if you’re not satisfied with these two. All of these sites list only public channels. If you want to join a private channel, you’ll have to ask one of its members to invite you.

At a time when the Indian stock market is peaking and has rallied immensely compared to global markets, there are companies that have not performed in the last 10 years. These are definitely a minor portion of the market considering there are hundreds of stocks that have turned multibagger since 2020. What went wrong with these stocks? Reasons vary from corporate governance, sectoral weakness, company specific and so on. But the more important question is, are these stocks worth buying?

Readhub from in


Telegram Readhub
FROM USA